1. Home
  2. STOK vs ULH Comparison

STOK vs ULH Comparison

Compare STOK & ULH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • ULH
  • Stock Information
  • Founded
  • STOK 2014
  • ULH 1932
  • Country
  • STOK United States
  • ULH United States
  • Employees
  • STOK N/A
  • ULH N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • ULH Trucking Freight/Courier Services
  • Sector
  • STOK Health Care
  • ULH Industrials
  • Exchange
  • STOK Nasdaq
  • ULH Nasdaq
  • Market Cap
  • STOK 740.9M
  • ULH 635.2M
  • IPO Year
  • STOK 2019
  • ULH 2005
  • Fundamental
  • Price
  • STOK $12.85
  • ULH $23.49
  • Analyst Decision
  • STOK Strong Buy
  • ULH Hold
  • Analyst Count
  • STOK 5
  • ULH 1
  • Target Price
  • STOK $27.75
  • ULH $29.00
  • AVG Volume (30 Days)
  • STOK 763.5K
  • ULH 63.8K
  • Earning Date
  • STOK 08-06-2025
  • ULH 07-24-2025
  • Dividend Yield
  • STOK N/A
  • ULH 1.78%
  • EPS Growth
  • STOK N/A
  • ULH N/A
  • EPS
  • STOK 0.88
  • ULH 2.31
  • Revenue
  • STOK $190,908,000.00
  • ULH $1,668,148,000.00
  • Revenue This Year
  • STOK $378.84
  • ULH N/A
  • Revenue Next Year
  • STOK N/A
  • ULH $7.88
  • P/E Ratio
  • STOK $14.68
  • ULH $10.23
  • Revenue Growth
  • STOK 2333.81
  • ULH N/A
  • 52 Week Low
  • STOK $5.35
  • ULH $20.60
  • 52 Week High
  • STOK $16.15
  • ULH $53.29
  • Technical
  • Relative Strength Index (RSI)
  • STOK 55.41
  • ULH 40.21
  • Support Level
  • STOK $12.25
  • ULH $23.40
  • Resistance Level
  • STOK $13.12
  • ULH $30.76
  • Average True Range (ATR)
  • STOK 0.82
  • ULH 1.70
  • MACD
  • STOK -0.06
  • ULH -0.40
  • Stochastic Oscillator
  • STOK 35.70
  • ULH 0.41

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About ULH Universal Logistics Holdings Inc.

Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.

Share on Social Networks: